Selling Sentinel: FDA Highlights Vision For Broader Role For Data Network At Brookings
This article was originally published in RPM Report
Executive Summary
FDA’s Janet Woodcock used her time at a conference on biomedical innovation to highlight ways to use FDA’s Sentinel network more broadly to standardize, and hopefully streamline comparative effectiveness research.
You may also be interested in...
Sentinel Offers Drug Firms ‘Unique’ Venue For Post-Market Studies, Pfizer Says
Pfizer’s experience in piloting an approach to using US FDA’s Sentinel data network for post-market research demonstrated the feasibility and benefits of doing so.
FDA’s Sentinel Likely To Outpace Traditional Post-Market Studies, But Will It Replace Them?
Pilot project for overactive bladder drug Mybretriq raises questions as to how Sentinel will affect sponsor’s risk-monitoring obligations.
Using Big Data For CER Will Be Harder Than Safety Studies – PCORI Investigator Platt
Richard Platt of PCORI’s National Patient-Centered Clinical Research Network discusses the future of comparative effectiveness research using big data during an expert roundtable session hosted by NEHI.